...
首页> 外文期刊>Diabetes, obesity & metabolism >Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects
【24h】

Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects

机译:钠葡萄糖共转运蛋白(SGLT)和葡萄糖转运蛋白(葡萄糖转运蛋白在2型糖尿病受试者的肾脏中表达

获取原文
获取原文并翻译 | 示例
           

摘要

The sodium-glucose co-transporters (SGLTs) are responsible for the tubular reabsorption of filtered glucose from the kidney into the bloodstream. The inhibition of SGLT2-mediated glucose reabsorption is a novel and highly effective strategy to alleviate hyperglycaemia in patients with type 2 diabetes mellitus (T2DM). However, the effectiveness of SGLT2 inhibitor therapy is diminished due, in part, to a compensatory increase in the maximum reabsorptive capacity (Tm) for glucose in patients with T2DM. We hypothesized that this increase in Tm could be explained by an increase in the tubular expression of SGLT and glucose transporters (GLUT) in these patients. To examine this, we obtained human kidney biopsy specimens from patients with or without T2DM and examined the mRNA expression of SGLTs and GLUTs. The expression of SGLT1 is markedly increased in the kidney of patients with T2DM, and SGLT1 mRNA is highly and significantly correlated with fasting and postprandial plasma glucose and HbA1c. In contrast, our data demonstrate that the levels of SGLT2 and GLUT2 mRNA are downregulated in diabetic patients, but not to a statistically significant level. These important findings are clinically significant and may have implications for the treatment of T2DM using strategies that target SGLT transporters in the kidney.
机译:钠葡萄糖共转运蛋白(SGLT)负责从肾脏的过滤葡萄糖的管状重吸收到血液中。 SGLT2介导的葡萄糖重吸收的抑制是一种新的和高效的策略,可缓解2型糖尿病(T2DM)患者的高血糖血症。然而,SGLT2抑制剂治疗的有效性部分由于T2DM患者葡萄糖的最大重吸收能力(TM)的补偿性增加而降低。我们假设可以通过这些患者中的SGLT和葡萄糖转运蛋白(葡萄糖转运蛋白(GLUC)的管状表达的增加来解释TM的这种增加。为了检查这一点,我们从有或没有T2DM的患者中获得人肾活检标本,并检查了SGLTS和GLUT的mRNA表达。在T2DM患者的肾脏中,SGLT1的表达显着增加,并且SGLT1 mRNA与禁食和餐后血浆葡萄糖和HBA1C具有高度和显着的相关性。相比之下,我们的数据表明,SGLT2和Glut2 mRNA的水平在糖尿病患者中下调,但没有统计学上显着的水平。这些重要的发现是临床显着性,并且可能对使用肾脏中的SGLT转运蛋白的策略治疗T2DM的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号